Sino Biopharm 1177

[winston]

vested

SINO BIOPHARM Annual NP May Grow Over 4x to Above RMB14B

SINO BIOPHARM (01177.HK) predicted the Group’s net profit for the year ended 31 December 2021 to increase by over 4 folds, as compared to last year to more than approximately RMB14 billion, against net profit for last year of RMB2.771 billion.

Dividend History
Announce Date Event Particular
2021/08/31 Interim D:HKD 0.0200
2021/05/24 Quarter 1 D:HKD 0.0200
2021/03/23 Final D:HKD 0.0200
2020/11/30 Quarter 3 D:HKD 0.0200

The substantial increase was mainly attributable to the satisfactory performance of the principal business.

During the year, sales of new products and high margin products increased, resulting in a notable year-on-year increase in overall revenue and gross profit margin.

Source: AAStocks Financial News

[winston]

vested

SINO BIOPHARM 2021 NP Rockets 427.2% to RMB14.61B; Final DPS HK4 Cents

SINO BIOPHARM (01177.HK) announced the result for the year ended 31 December, 2021.

The Group recorded revenue of RMB26.86 billion, an increase of 13.6% over last year.

Net profit was RMB14.61 billion, an increase of 427.2% over last year.

Underlying profit was RMB2.93 billion, an increase of 26.6% over last year.

Earnings per share were approximately RMB77.83 cents.

Dividend History
Announce Date Event Particular
2021/08/31 Interim D:HKD 0.0200
2021/05/24 Quarter 1 D:HKD 0.0200
2021/03/23 Final D:HKD 0.0200
2020/11/30 Quarter 3 D:HKD 0.0200

A final dividend of HK4 cents per share was declared. Together with the first quarterly dividend of HK2 cents per share and the second quarterly dividend of HK2 cents per share, the total dividend of the year amounted to HK8 cents per share.

Source: AAStocks Financial News

[winston]

vested

Sino Biopharmaceutical (1177 HK)
2021: Satisfactory Results; Targets Double-Digit Revenue Growth In 2022 and 10
Innovative Product Launches In Three Years

Sino Biopharm reported a satisfactory set of results for 2021 with revenue growing
13.6% yoy and adjusted net earnings increasing 26.6% yoy.

The company targets to expand revenue by double digits in 2022.

Its R&D efforts are also bearing fruit, and the company expects to launch about 10 innovative products in the next three years.

Maintain BUY and target price of HK$7.50.

Source: UOBKH

https://research.uobkayhian.com/content ... 49888c7414

[winston]

vested

SINO BIOPHARM Interim Profit Slips 78% Max.

SINO BIOPHARM (01177.HK) issued a profit warning.

The Group’s profit for the six months ended 30 June 2022 decreased by up to approximately 78% over the same period last year to approximately RMB1.871 billion.

While the Group’s share of profit of the associate decreased, the principal business of the Group performed as expected during the period, with steady growth in results year-on-year.

Dividend History
Announce Date Event Particular
2022/03/31 Final D:HKD 0.0400
2021/08/31 Interim D:HKD 0.0200
2021/05/24 Quarter 1 D:HKD 0.0200
2021/03/23 Final D:HKD 0.0200

Source; AAStocks Financial News

[winston]

vested

Sino Biopharmaceutical Ltd (1177 HK) - Mixed 1H with lower vaccine profit

Headquartered in Hong Kong and Beijing, Sino Biopharmaceutical (中国生物制药有限公司, SBP) is a leading drug manufacturer in China with a competitive drug portfolio, strong sales force, and promising pipeline.

FY21 revenue contributors by major disease areas: oncology 34%, hepatitis ~15.9%, orthopedic 8.8%, respiratory system 6.2%, anti-infectious medicines 5.6% and others 31.3%.

SBP is the industry leader for liver diseases drugs, a segment with annual sales revenue exceeding CNY 1b and accounts for about a quarter of the overall sales of the liver disease market in China.

While the ongoing healthcare reforms, focusing on price and quality controls, should weigh on margins and may continue to trigger occasional volatility in sector share prices, Covid-19’s impact should also lend greater policy support for domestic drug innovation, which benefits pharmas (such as SBP) with strong R&D focus and growing pipelines.

SBP has a 15.03% equity stake in vaccine maker Sinovac Life Sciences, a subsidiary of Sinovac. Management targets for over HKD100b revenue by 2030 and expects close to two thirds would be derived from innovative products. BUY.

Source: OCBC

[winston]

vested

SINO BIOPHARM(1177)

Analysis：

Sino Biopharmaceutical Limited (01177) announces that the category I innovative medicine “TDI01”has been approved by the National Medical Products Administration of China on September 2022 to commence clinical trial for the treatment of Novel Coronavirus Pneumonia a (“COVID-19”).

TDI01 works by inhibiting viral attack and replication through highly selective inhibition of ROCK2 target to achieve anti-viral effects, which is a novel anti-viral mechanism that has shown significant inhibition of novel coronavirus in vitro and in vivo animal experiments, as well as anti-inflammatory and anti-fibrotic effects.

TDI01 is a category I small molecule oral medicine for the treatment of COVID-19 with novel mechanism and brand-new target and structure, which differentiates itself from the traditional anti-novel coronavirus medicines currently under development worldwide and in China.

TDI01 is the world`s first innovative small molecule medicine that inhibits novel coronavirus infection to host cells by highly selective inhibition of ROCK2 kinase, thereby achieving significant anti-viral effect.

TDI01 has now completed the Phase I clinical trial in the United States and has also completed the human race bridging study of Phase I clinical trial in China.

Previously, TDI01 was approved for clinical trials in China and the United States for the treatment of idiopathic pulmonary fibrosis and in China for the treatment of pneumoconiosis.

The approval of TDI01 for clinical trials in three major indications in the respiratory field will further increase the Group`s product pipeline of innovative drugs in the respiratory field and bring new treatment option to patients with respiratory diseases.

Strategy：
Buy-in Price: $4.20, Target Price: $4.60, Cut Loss Price: $3.89

Source: Phillips

[winston]

vested

SINO BIOPHARM 3Q Rev. Lifts 21.3% YoY to About RMB7.473B

SINO BIOPHARM (01177.HK) announced that, in the third quarter of 2022, the Group recorded revenue of approximately RMB7.473 billion, an increase of approximately 21.3% over the same period last year; in the first three quarters of 2022, the Group recorded revenue of approximately RMB22.667 billion, an increase of approximately 10.5% over the same period last year.

Source: AAStocks Financial News

http://www.aastocks.com/en/stocks/news/ ... t-news/HK6

[winston]

vested

Sino Biopharmaceutical (1177 HK)

9M22 Revenue Growth In Line; Guiding For Double-digit Revenue And Earnings
Growth In 2022

Sino Biopharm recorded revenue growth of 10.5% yoy in 9M22, in line with our growth
estimates for 2022.

The company expects steady revenue growth in 4Q22, and targets revenue to expand by double digits in 2022 and by 10-15% yoy in 2023.

Moreover, the company has been refining its R&D and sales strategies to focus more on innovation.

Maintain HOLD with a target price of HK$4.00.

Source: UOBKH

https://research.uobkayhian.com/content ... 67322d871d

[winston]

vested

ENTERED INTO EXCLUSIVE PROMOTION AGREEMENT

The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the
“Company” or “Sino Biopharm”) announces that Chia-Tai Tianqing Pharmaceutical
Group Co., Ltd. (“Chia-Tai Tianqing”), a subsidiary of the Company, entered into an exclusive promotion agreement with Ping An-Shionogi Co., Ltd. (“Ping An-Shionogi”), pursuant to which Chia-Tai Tianqing is granted exclusive promotion rights for
Ensitrelvir, a treatment for new coronavirus infection (“COVID-19”), in Mainland
China for an initial period of five years.

http://iis.aastocks.com/20221229/10555422-0.PDF

[winston]

vested

SINO BIOPHARMACEUTICAL LTD (1177 HK)

Recommendation : BUY
Fair Value : HKD 6.50

CONSTRUCTIVE GUIDANCE .

Exclusive promotion agreement for Ensitrelvir was entered on 29th December 2022 with Ping An-Shionogi, for which SBP’s subsidiary Chia-Tai Tianqing would be granted promotion rights for an initial five years in Mainland China.

Guides for 12-15% sales growth in 2023, with key innovative drugs expected to commercialise in 2024.

By 2030, SBP believes one third of sales could come from business development.

Headquartered in Hong Kong and Beijing, Sino Biopharmaceutical (中国生物制药有限公司, SBP) is a leading drug manufacturer in China with a competitive drug portfolio, strong sales force, and promising pipeline.

FY21 revenue contributors by major disease areas: oncology 34%, hepatitis ~15.9%, orthopedic 8.8%, respiratory system 6.2%, anti-infectious medicines 5.6% and others 31.3%.

SBP is the industry leader for liver diseases drugs, a segment with annual sales revenue exceeding CNY 1b and accounts for about a quarter of the overall sales of the liver disease market in China.

While the ongoing healthcare reforms, focusing on price and quality controls, may weigh on margins and may continue to trigger occasional volatility in sector share prices, Covid-19’s impact should also lend greater policy support for domestic drug innovation, which benefits pharmas (such as SBP) with strong R&D focus and growing pipelines.

SBP has a 15.03% equity stake in vaccine maker Sinovac Life Sciences, a subsidiary of Sinovac.

Management targets for over HKD100b revenue by 2030 and expects close to two thirds would be derived from innovative products.

Source: OCBC